“The existing circumstance has uncovered some structural weaknesses while in the EU’s medicines source chain as well as a significant dependence on non-EU nations for active pharmaceutical ingredients,” Kyriakides claimed. She advised that supply chain issues be dealt with in an EU pharmaceutical approach envisioned for being released by the